The medtech giant said it plans to invest $50 million over five years in the Pune, India location. In a post on LinkedIn, Medtronic said:
“We are proud to mark a significant milestone with the inauguration of our new Diabetes Global Capability Center in India — a bold step forward in transforming diabetes care. This center exemplifies our unwavering commitment to advancing healthcare technology and delivering meaningful innovations that improve lives.”
Medtronic also said the investment reflects its long-term commitment to India’s healthcare ecosystem. It expects the center to create 300 new jobs in its first year. Beyond that, the company has plans to expand further in the years ahead. That includes across capabilities like patient financial services, digital technology, customer care and advanced analytics.
The investment in a diabetes-related center comes at an interesting time for Medtronic, which announced last month that it planned to separate the Diabetes unit. The move sought to create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. At the same time, it creates an independent, scaled leader in diabetes.
Medtronic announced last week that the new company, once separated, will be called “MiniMed,” marking a return to the name of the insulin pump company it bought in 2001.
The company says choosing MiniMed honors the company’s roots and reflects a 40-year history of transforming diabetes care.
